Menu
Menu
This webinar is presented in Chinese.
Alamut™ Visual Plus empowers clinical genomics teams with the tools needed to interpret genetic variants with speed and confidence. This webinar, hosted for the Chinese user community by Yi Lian, Product Director at SOPHiA GENETICS, demonstrates how Alamut™ Visual Plus v2.0 accelerates variant workflows from enhanced navigation and splicing prediction to visualization of bioinformatics files and customizable reporting.
This webinar is presented in Spanish.
Alamut™ Visual Plus empowers clinical genomics teams with the tools needed to interpret genetic variants with speed and confidence. This webinar, hosted for the Spanish user community by David Munoz, Alamut™ Visual Plus Expert at SOPHiA GENETICS, demonstrates how Alamut™ Visual Plus v2.0 accelerates variant workflows from enhanced navigation and splicing prediction to visualization of bioinformatics files and customizable reporting.
Accurate and comprehensive genomic insights are increasingly essential for the diagnosis, classification, and risk stratification of myeloid malignancies — spanning single nucleotide variants, gene fusions, and large chromosomal aberrations. Yet consolidating these layers of genomic data into routine clinical workflows remains a significant bottleneck for many laboratories.
In this webinar, join Cecilia Lang, Biochemist and Head of Cytogenetics at Laboratorio de Especialidades Bioquímicas (LEB, Argentina), and Brandon Bullough, Product Marketing Director at SOPHiA GENETICS, as they explore how NGS-based molecular profiling with the SOPHiA DDM™ Myeloid Solution v2 (MYS2) can consolidate laboratory workflows and accelerate time-to-insights in the analysis of myeloid malignancies.
Brandon Bullough will open with an overview of SOPHiA DDM™ MYS2, tracing the need that drove its development and what sets it apart as a comprehensive myeloid solution. Cecilia Lang will then share her team's real-world experience implementing SOPHiA DDM™ MYS2 at a cytogenetics-focused reference center in Latin America — including its practical impact on day-to-day workflows and her perspective on where the field is headed.
Learning objectives
Speakers
Cecilia Lang
Head of Cytogenetics and FISH
Laboratorio de Especialidades Bioquimicas, LEB
Andrea Bender
Head of Molecular Biology
Laboratorio de Especialidades Bioquimicas, LEB
Brandon Bullough
Product Marketing Director, Blood Cancers
SOPHiA GENETICS
SOPHiA GENETICS and Myriad Genetics have joined forces in a unique partnership combining Myriad’s centralized CDx and regulatory expertise with SOPHiA GENETICS’ decentralized, data-driven platform.
In this engager we explore how a groundbreaking industry collaboration is rethinking current CDx approaches through a hybrid model designed for rapid scalability and access to precision medicine. Attendees will:
Topics:
Speakers:
Scientific innovation and the unprecedented surge in health data generated every day are transforming our understanding of disease and reshaping the future of precision medicine. As FDA-approved biomarker-targeted therapies continue to expand rapidly, BioPharma companies face increasing pressure to bring them to the market faster to the patients who need them the most. As such, the delivery of robust, accurate, and scalable end-to-end diagnostic solutions across the globe has become essential.
In this talk, we will explore how SOPHiA GENETICS empowers BioPharma to advance precision medicine by harnessing AI-powered analytics and next-generation genomics solutions, improving access to new therapies worldwide and helping close critical health equity gaps.
Speaker:
Jess Lambe, MBA
VP & Managing Director BioPharma Business Development, SOPHiA GENETICS
Pharmacogenomics has been invaluable in reducing adverse drug reactions, improving dosing accuracy and increasing confidence in treatment selection across high risk and commonly prescribed medications. However, real-world implementation of pharmacogenomics is extremely challenging.
This webinar will use a case study, featuring real-world clinical data, to outline how pharmacogenomics testing through NGS can improve detection of variants, and support safer, more confident decision-making.
Case study
Fluoropyrimidines like 5-FU remain essential in oncology, but patient safety depends on efficient DPD metabolism. Standard genotyping captures only a small subset of DPYD variants, while NGS can uncover broader variability with potential clinical relevance.
In this webinar Dr. Nicolas Picard (University Hospital of Limoges) will present results from an NGS research study of 1,145 patients using the SOPHiA DDM™ Community PGx Solution, highlighting rare variants and CNVs that standard testing may miss - an important consideration following the FDA’s recent boxed warning for capecitabine.
Sevana Yaghoubian will then introduce SOPHiA GENETICS’ new extended PGx application covering 74 genes with star allele detection and integrated HLA and mtDNA analysis.
In this webinar, you will:
Speakers
Nicolas Picard, PharmD, PhD, Head of French Speaking Network of Pharmacogenetics (RNPGx), Limoges University Hospital, France
Nicolas Picard is full professor of pharmacology at the Faculty of Pharmacy, University of Limoges (France), and hospital biologist in the Department of pharmacology, toxicology and pharmacovigilance at Limoges University Hospital. A pharmacist since 2002, he obtained his PhD in Pharmacology in 2005. He heads the Department of physiology and pharmacology at the Faculty of Pharmacy, where he teaches fundamental and clinical pharmacology, and is jointly responsible for the molecular genetics unit of the University Hospital, leading its clinical pharmacogenetics section. His research within the Inserm “Pharmacology & Transplantation” Unit has evolved from in vitro studies of drug metabolism and disposition to clinical research, and now focuses primarily on the implementation of pharmacogenetics in transplantation, psychiatry, and geriatrics. He has authored around 100 peer-reviewed publications and currently serves as President of the Francophone Network of Pharmacogenetics (RNPGx) which brings together experts from France, Belgium, Switzerland, Tunisia, and Quebec.
Sevana Yaghoubian, Senior Director of Genomics Product Management, SOPHiA GENETICS
Sevana Yaghoubian has extensive experience in the field of genomics and molecular diagnostics. She is currently a Senior Director of Genomics Product Management at SOPHiA GENETICS, where they lead a team and is responsible for various aspects of product management, marketing, and business development. During her time at SOPHiA GENETICS, she achieved significant growth and successfully launched several new products in the areas of oncology, rare diseases, and precision medicine. Sevana Yaghoubian holds an MSc in Molecular Biology from the University of Toronto.
MTAP deletion is rapidly emerging as a clinically actionable biomarker across multiple tumor types, frequently associated with a poor prognosis. While this is driving new therapeutic opportunities, it also exposes a major challenge for precision oncology trials: accurately testing for difficult and novel biomarkers. In Europe, especially, this gap continues to delay clinical trial enrolment and slow therapeutic progress.
In this webinar, we will explore how SOPHiA GENETICS, in partnership with ARC Regulatory, is addressing these challenges by implementing a comprehensive genomic profiling assay to enable biomarker identification and patient enrolment for clinical trials across Europe. By combining SOPHiA GENETICS’ AI-powered technology with ARC Regulatory’s expertise in assay implementation and workflow validation, we accelerate CTA development in instances such as MTAP deletion. Together, we aim to reduce regulatory risk in clinical research programs, shorten timelines for clinical trial recruitment, and broaden clinical trial recruitment in Europe.
Join us to gain insights into the nuances of European clinical trial testing and how robust genomic solutions can advance precision oncology research and ultimately improve patient outcomes.
Speakers:
Whole-exome sequencing (WES) is widely used in both clinical and research settings, but current implementations require trade-offs between genomic breadth, sensitivity, and workflow complexity. As a result, labs typically maintain multiple assays to meet different kinds of testing.
In this GEN webinar, Guilherme Yamamoto, MD, PhD, and Sevana Yaghoubian will present a novel whole-exome assay for detecting high-confidence variants across multiple applications. Using examples from rare diseases, newborn and carrier screening, and targeted analysis for cardiovascular, neurological, ocular, and metabolic disorders, they will explore how combining targeted probe enhancements with robust analytics improves performance in challenging genomic regions. They will also discuss how these enhanced exome assays can extend beyond germline testing through secondary screening for common somatic variants in hematologic cancers. Key takeaways from the webinar include:
Speakers:
Guilherme Yamamoto, MD, PhD
Head of Genomics and Bioinformatics Innovation
Dasa
Sevana Yaghoubian, MSc
Senior Director Genomics
SOPHiA GENETICS
Streamline variant analysis in Japanese - This webinar is presented in Japanese.
Alamut™ Visual Plus empowers clinical genomics teams with the tools needed to interpret genetic variants with speed and confidence. This webinar, hosted for the Japanese user community by Takeshi Sumida, Implementation Scientist at SOPHiA GENETICS, demonstrates how Alamut™ Visual Plus v2.0 accelerates variant workflows from enhanced navigation and splicing prediction to visualization of bioinformatics files and customizable reporting.
Speaker: Persephone du Parcq, Lead Clinical/Translational Scientist, Synnovis, UK
In this webinar, Dr. Persephone du Parcq shares how Synnovis has deployed the MSK-ACCESS™ powered with SOPHiA DDM™ to support precision oncology through minimally invasive liquid biopsy testing.
The webinar explores current clinical applications of ctDNA analysis, its demonstrated utility in routine healthcare, and key considerations around assay selection, validation strategies, and interpretation challenges including germline findings and clonal haematopoiesis. Practical insights into clinical impact, operational achievements to date, and lessons learned from clinical implementation are also discussed.
Finally, the session looks ahead to future directions for liquid biopsy in oncology, including opportunities to expand clinical adoption and improve patient care through advanced genomic technologies.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.